The Food and Drug Administration approved Novo Nordisk's weight-loss drug Wegovy on Friday for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
<p>WASHINGTON — The U.S.
</p><p>Patients who are obese or overweight are at &quot;a higher risk of cardiovascular death, heart attack and stroke.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early TrialI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
続きを読む »
FDA approves weight-loss drug Wegovy to reduce heart-disease risksThe FDA approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind.
続きを読む »
Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
続きを読む »
Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drugThe injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.
続きを読む »
FDA approves Wegovy to reduce heart attack and stroke riskThe U.S. Food and Drug Administration approved a label change that expands the use of the drug in Wegovy. It was previously approved to treat obesity.
続きを読む »
FDA approves Wegovy for lowering heart attack and stroke risk in overweight patientsThe popular weight-loss drug can now be used to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or who have obesity, the FDA said.
続きを読む »